Reports
Reports
Sale
The global analgesics market attained a value of USD 71.90 billion in 2023 driven by increasing cases of chronic pain due to the rising old age population past 60 years of age. The market is anticipated to grow at a CAGR of 4.5% during the forecast period of 2024-2032 to attain a value of USD 106.84 billion by 2032.
The global analgesics market is driven by the increasing geriatric population globally. In 2017, the people over the age of 60, were recorded to be 950-1000 million. By the year 2050, these numbers are expected to grow rapidly to reach 2100 million, accounting for about 21% of the overall global population. Due to their susceptibility to chronic and lifestyle diseases, the rising population of older people will substantially contribute to the sales of analgesics. Further, permission by the United States Food and Drug Administration (USFDA) for the utilisation of a strong drug pipeline with efficacious drugs is expected to aid the analgesics market growth in the forecast period.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Analgesics Market Overview
3.1 Global Analgesics Market Historical Value (2017-2023)
3.2 Global Analgesics Market Forecast Value (2024-2032)
4 Global Analgesics Market Landscape
4.1 Global Analgesics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Analgesics Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Drug Class
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by Pain Type
4.2.5 Analysis by Application
4.2.6 Analysis by Distribution Channel
5 Global Analgesics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Analgesics Market Segmentation
6.1 Global Analgesics Market by Type
6.1.1 Market Overview
6.1.2 Prescription Analgesics
6.1.3 OTC Analgesics
6.2 Global Analgesics Market by Drug Class
6.2.1 Market Overview
6.2.2 Opioids
6.2.3 NSAID
6.2.4 Others
6.3 Global Analgesics Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Topical
6.3.5 Transdermal
6.3.6 Rectal
6.4 Global Analgesics Market by Pain Type
6.4.1 Market Overview
6.4.2 Musculoskeletal Pain
6.4.3 Surgical and Trauma Pain
6.4.4 Cancer Pain
6.4.5 Neuropathic Pain
6.4.6 Migraine
6.4.7 Obstetrical Pain
6.4.8 Fibromyalgia
6.4.9 Pain due to burns
6.4.10 Dental/Facial Pain
6.4.11 Pediatric Pain
6.4.12 Others
6.5 Global Analgesics Market by Application
6.5.1 Market Overview
6.5.2 Internal Analgesics
6.5.3 External Analgesics
6.6 Global Analgesics Market by End User
6.6.1 Market Overview
6.6.2 Hospital Pharmacy
6.6.3 Retail Pharmacy
6.6.4 Other
6.7 Global Analgesics Market by Region
6.7.1 Market Overview
6.7.2 North America
6.7.3 Europe
6.7.4 Asia Pacific
6.7.5 Latin America
6.7.6 Middle East and Africa
7 North America Analgesics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Analgesics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Analgesics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Analgesics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Analgesics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Bayer AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 GlaxoSmithKline plc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Pfizer Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sanofi
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 F. Hoffmann-La Roche Ltd.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Endo Pharmaceuticals, Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Bristol-Myers Squibb Company
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Assertio Therapeutics, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Janssen Pharmaceuticals
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Novartis AG
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Teva Pharmaceuticals
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 AbbVie Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Purdue Pharmaceuticals L.P.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Boehringer Ingelheim International GmbH
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
18 Global Analgesics Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Globally, analgesics market reached a value of USD 71.90 billion in 2023.
The market is projected to expand at a CAGR of 4.5% from 2024 to 2032, growing to USD 106.84 billion by 2032.
The major drivers of the industry such as rising disposable incomes, increasing population, increasing health consciousness, and increasing geriatric population are expected to aid the industry growth.
The rising R&D activities aimed at producing more effective analgesics with lesser side effects is a major trend guiding the growth of the market.
The major regional markets for the product are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The leading types of the product in the industry are prescription and OTC analgesics.
Opioids and NSAID, among others, are the leading drug classes available in the market.
The leading ROA types in the industry are into oral, parenteral, topical, transdermal, and rectal.
The major pain types covered in the report are musculoskeletal pain, surgical and trauma pain, cancer pain, neuropathic pain, migraine, obstetrical pain, fibromyalgia, pain due to burns, dental/facial pain, paediatric pain, and others.
The leading applications of the product are internal and external analgesics.
The major players in the industry are Bayer AG, GlaxoSmithKline PLC, Pfizer Inc., Sanofi, and others.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.